Trial of Lixisenatide in Early Parkinson’s DiseaseWassilios G. Meissner, Olivier Rascol, Olivier Colin et al.|New England Journal of Medicine|2024Cited by 302
Real-life prognosis of neurological complications of botulinum toxin: A nationwide pharmacovigilance study of adverse drug reactions reported in France between 1994 and 2020Vincent T. Carpentier, Kévin Bihan, Nicolas Weiss et al.|Annals of Physical and Rehabilitation Medicine|2025Cited by 3
AZP2006 in Progressive Supranuclear Palsy: A Multi-Centre, Randomized, Phase 2a Trial Assessing Safety and Biomarker OutcomesJean‐Christophe Corvol, Luc Defebvre, Mickaël Alexandre Obadia et al.|SSRN Electronic Journal|2024Cited by 0
AZP2006 in Progressive Supranuclear Palsy: A Multi-Centre, Randomized, Phase 2a Trial Assessing Safety and Biomarker OutcomesJean‐Christophe Corvol, Luc Defebvre, Mickaël Alexandre Obadia et al.|SSRN Electronic Journal|2024Cited by 0
<scp>AZP2006</scp> in Progressive Supranuclear Palsy: Outcomes from a Phase 2a Multicenter, Randomized Trial, and Open‐Label Extension on Safety, Biomarkers, and Disease ProgressionJean‐Christophe Corvol, Luc Defebvre, Mickaël Alexandre Obadia et al.|Movement Disorders|2025Cited by 0